77
IRUS TotalDownloads
Altmetric
Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification
File | Description | Size | Format | |
---|---|---|---|---|
jpr-213912-rational-treatment-of-chemotherapy-induced-peripheral-neurop.pdf | Published version | 2.98 MB | Adobe PDF | View/Open |
Title: | Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification |
Authors: | Anand, P Elsafa, E Privitera, R Naidoo, K Yiangou, Y Donatien, P Gabra, H Wasan, H Kenny, L Rahemtulla, A Misra, P |
Item Type: | Journal Article |
Abstract: | Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) with associated chronic pain is a common and disabling condition. Current treatments for neuropathic pain in CIPN are largely ineffective, with unfavorable side-effects. The capsaicin 8% patch (capsaicin 179 mg patch) is approved for the treatment of neuropathic pain: a single topical cutaneous application can produce effective pain relief for up to 12 weeks. We assessed the therapeutic potential of capsaicin 8% patch in patients with painful CIPN, and its mechanism of action. Patients and methods: 16 patients with chronic painful CIPN (mean duration 2.5 years), in remission for cancer and not receiving chemotherapy, were treated with 30 min application of capsaicin 8% patch to the feet. Symptoms were monitored using the 11-point numerical pain rating scale (NPRS), and questionnaires. Investigations were performed at baseline and three months after patch application, including skin biopsies with a range of markers, and quantitative sensory testing (QST). Results: Patients reported significant reduction in spontaneous pain (mean NPRS: −1.27; 95% CI 0.2409 to 2.301; p=0.02), touch-evoked pain (−1.823; p=0.03) and cold-evoked pain (−1.456; p=0.03). Short-Form McGill questionnaire showed a reduction in neuropathic (p=0.0007), continuous (p=0.01) and overall pain (p=0.004); Patient Global Impression of Change showed improvement (p=0.001). Baseline skin biopsies showed loss of intra-epidermal nerve fibers (IENF), and also of sub-epidermal nerve fibers quantified by image analysis. Post-patch application skin biopsies showed a significant increase towards normalization of intra-epidermal and sub-epidermal nerve fibers (for IENF: structural marker PGP9.5, p=0.009; heat receptor TRPV1, p=0.027; regenerating nerve marker GAP43, p=0.04). Epidermal levels of Nerve Growth Factor (NGF), Neurotrophin-3 (NT-3), and Langerhans cells were also normalized. QST remained unchanged and there were no systemic side-effects, as in previous studies. Conclusion: Capsaicin 8% patch provides significant pain relief in CIPN, and may lead to regeneration and restoration of sensory nerve fibers ie, disease modification. |
Issue Date: | 3-Jul-2019 |
Date of Acceptance: | 13-Jun-2019 |
URI: | http://hdl.handle.net/10044/1/71611 |
DOI: | https://dx.doi.org/10.2147/JPR.S213912 |
ISSN: | 1178-7090 |
Publisher: | Dove Medical Press |
Start Page: | 2039 |
End Page: | 2052 |
Journal / Book Title: | Journal of Pain Research |
Volume: | 12 |
Copyright Statement: | © 2019 Anand et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php) |
Sponsor/Funder: | Astellas Pharma Europe Ltd |
Funder's Grant Number: | P08100255515 |
Keywords: | Science & Technology Life Sciences & Biomedicine Clinical Neurology Neurosciences & Neurology capsaicin neuropathic pain chemotherapy skin biopsy NERVE GROWTH-FACTOR DOUBLE-BLIND TOPICAL CAPSAICIN CONTROLLED-TRIAL CLINICAL-TRIAL OPEN-LABEL VINCRISTINE NGX-4010 OXALIPLATIN PACLITAXEL capsaicin chemotherapy neuropathic pain skin biopsy 1103 Clinical Sciences 1115 Pharmacology and Pharmaceutical Sciences |
Publication Status: | Published |
Appears in Collections: | Department of Medicine (up to 2019) |